WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced that data from the Phase 3 REACH2 study have been published in The New England Journal of Medicine demonstrating that ruxolitinib (Jakafi) improves outcomes across a range of efficacy measures in patients with steroid-refractory acute graft-versus-host disease (GVHD) compared to best available therapy (BAT). The results of REACH2, the first Phase 3 study of ruxolitinib in acute GVHD to have met its primary endpoint, reinforce findings from the previously-reported Phase 2 REACH1 study.
In REACH2, patients treated with ruxolitinib experienced a significantly greater overall response rate (ORR) vs. BAT (62% vs. 39%; p<0.001) at Day 28, the primary endpoint of the study. For the key secondary endpoints, patients treated with ruxolitinib maintained significantly higher durable ORR (40% vs. 22%; p<0.001) at Day 56. In addition, ruxolitinib was associated with longer median failure free survival (FFS) than BAT (5.0 months vs. 1.0 months; hazard ratio 0.46, 95% CI, 0.35 to 0.60) and showed a positive trend with other secondary endpoints, including duration of response1,2.
No new safety signals were observed, and the ruxolitinib safety profile in REACH2 was consistent with that seen in previously reported studies in steroid-refractory acute GVHD. The most frequently reported adverse events among study participants were thrombocytopenia and anemia. While 38% and 9% of patients required ruxolitinib and BAT dose modifications, the number of patients who discontinued treatment due to AEs was low (11% and 5%, respectively)1,2.
The results from the REACH2 study reinforce findings from the pivotal REACH1 trial and demonstrate the potential that ruxolitinib has to effectively and safely improve outcomes for patients with GVHD, said Peter Langmuir, M.D., Group Vice President, Oncology Targeted Therapies, Incyte. We are committed to continuing our research in GVHD with the goal of providing more effective treatment options for patients living with this disease, and look forward to the results of the REACH3 study in steroid-refractory chronic GVHD later this year.
The REACH2 data were also accepted as an oral presentation as part of the Presidential Symposium at the European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting to be held 30 August to 2 September in Madrid, Spain.
Patients with acute graft-versus-host disease face life-threatening challenges with limited treatment options, particularly for the nearly half of individuals who do not respond to initial steroid therapy, said Robert Zeiser, University Hospital Freiburg, Department of Haematology, Oncology and Stem Cell Transplantation, Freiburg, Germany. "These new data from REACH2 showing superiority of ruxolitinib over current standard-of-care therapies add to a growing body of evidence on how targeting the JAK pathway can be an effective strategy in this difficult-to-treat condition.
In 2019, Jakafi (ruxolitinib) was approved by the U.S. Food and Drug Administration for the treatment of steroid-refractory acute GVHD in adult and pediatric patients 12 years and older, based on the positive results of the Phase 2 REACH1 trial6. The Phase 3 REACH3 study in patients with steroid-refractory chronic GVHD is ongoing and results are expected in the second half of this year. Jakafi is marketed by Incyte in the U.S.; ruxolitinib (Jakavi) is licensed to Novartis ex-U.S.
The NEJM publication of the REACH2 results is available online.
About REACH2
REACH2 (NCT02913261), a randomized, open-label, multicenter Phase 3 study sponsored by Novartis and conducted in collaboration with and co-funded by Incyte , is evaluating the safety and efficacy of ruxolitinib compared with best available therapy in patients with steroid-refractory acute GVHD.
The primary endpoint was overall response rate (ORR) at Day 28, defined as the proportion of patients demonstrating a best overall response (complete response or partial response). Secondary endpoints include durable ORR at Day 56, ORR at Day 14, duration of response, overall survival and event-free survival, among others. For more information about the study, please visit https://clinicaltrials.gov/ct2/show/NCT02913261.
About REACH
The REACH clinical trial program evaluating ruxolitinib in patients with steroid-refractory GVHD, includes the randomized pivotal Phase 3 REACH2 and REACH3 trials, conducted in collaboration with Novartis. The ongoing REACH3 trial is evaluating patients with steroid-refractory chronic GVHD with results expected later this year. For more information about the REACH3 study, please visit https://clinicaltrials.gov/ct2/show/NCT03112603.
The REACH program was initiated with the Incyte-sponsored REACH1 trial, a prospective, open-label, single-cohort, multicenter, pivotal Phase 2 trial (NCT02953678) evaluating Jakafi in combination with corticosteroids in patients with steroid-refractory grade II-IV acute GVHD. For more information about the study, including trial results, please visit https://clinicaltrials.gov/show/NCT02953678.
About Jakafi (ruxolitinib)
Jakafi is a first-in-class JAK1/JAK2 inhibitor approved by the U.S. FDA for the treatment of polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea, in adults with intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF and for the treatment of steroid-refractory acute GVHD in adult and pediatric patients 12 years and older.
Jakafi is marketed by Incyte in the United States and by Novartis as Jakavi (ruxolitinib) outside the United States. Jakafi is a registered trademark of Incyte Corporation. Jakavi is a registered trademark of Novartis AG in countries outside the United States.
Important Safety Information
Jakafi can cause serious side effects, including:
Low blood counts: Jakafi (ruxolitinib) may cause your platelet, red blood cell, or white blood cell counts to be lowered. If you develop bleeding, stop taking Jakafi and call your healthcare provider. Your healthcare provider will perform blood tests to check your blood counts before you start Jakafi and regularly during your treatment. Your healthcare provider may change your dose of Jakafi or stop your treatment based on the results of your blood tests. Tell your healthcare provider right away if you develop or have worsening symptoms such as unusual bleeding, bruising, tiredness, shortness of breath, or a fever.
Infection: You may be at risk for developing a serious infection during treatment with Jakafi. Tell your healthcare provider if you develop any of the following symptoms of infection: chills, nausea, vomiting, aches, weakness, fever, painful skin rash or blisters.
Skin cancers: Some people who take Jakafi have developed certain types of non-melanoma skin cancers. Tell your healthcare provider if you develop any new or changing skin lesions.
Increases in cholesterol: You may have changes in your blood cholesterol levels. Your healthcare provider will do blood tests to check your cholesterol levels during your treatment with Jakafi.
The most common side effects of Jakafi include: for certain types of MF and PV - low platelet or low red blood cell counts, bruising, dizziness, headache, and diarrhea; and for acute GVHD low platelet, red or white blood cell counts, infections, and fluid retention.
These are not all the possible side effects of Jakafi. Ask your pharmacist or healthcare provider for more information. Tell your healthcare provider about any side effect that bothers you or that does not go away.
Before taking Jakafi, tell your healthcare provider about: all the medications, vitamins, and herbal supplements you are taking and all your medical conditions, including if you have an infection, have or had tuberculosis (TB), or have been in close contact with someone who has TB, have or had hepatitis B, have or had liver or kidney problems, are on dialysis, have a high level of fat in your blood (high blood cholesterol or triglycerides), had skin cancer or have any other medical condition. Take Jakafi exactly as your healthcare provider tells you. Do not change or stop taking Jakafi without first talking to your healthcare provider.
Women should not take Jakafi while pregnant or planning to become pregnant. Do not breast-feed during treatment with Jakafi and for 2 weeks after the final dose.
Full Prescribing Information, which includes a more complete discussion of the risks associated with Jakafi, is available at http://www.jakafi.com.
About Incyte
Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.
Forward-Looking Statements
Except for the historical information set forth herein, the matters set forth in this press release, including statements about the REACH2 data, when results from the REACH3 study will be available, the effect of the REACH2 results on patients with GVHD, and the overall REACH program, contain predictions, estimates and other forward-looking statements.
These forward-looking statements are based on the Companys current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by the FDA; the Companys dependence on its relationships with its collaboration partners; the efficacy or safety of the Companys products and the products of the Companys collaboration partners; the acceptance of the Companys products and the products of the Companys collaboration partners in the marketplace; market competition; sales, marketing, manufacturing and distribution requirements; greater than expected expenses; expenses relating to litigation or strategic activities; and other risks detailed from time to time in the Companys reports filed with the Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2019. The Company disclaims any intent or obligation to update these forward-looking statements.
References
The rest is here:
- Following Their Calling to Help Young Cancer Patients and Beyond - Stanford Children's Health - September 28th, 2024
- Greenberg Regenerative Medicine Celebrates Nearing 2 Years of Success with Pioneering VSEL Therapy - PR.com - September 28th, 2024
- Discovery clears hurdle in growing organs for transplants : Newsroom - UT Southwestern - September 26th, 2024
- Cell Therapy Market is Expected to Gain USD 60696.42 Million with a Growing CAGR of 19.20% by 2030 - openPR - September 25th, 2024
- Stem Cell Therapy Market To Reach USD 44 Billion By 2032 (Updated 2024) - Market.us Media - United States Market News - September 25th, 2024
- Doctors cured her sickle-cell disease. So why is she still in pain? - Nature.com - September 23rd, 2024
- The new frontier of luxury travel is a $44,000 course of stem cells and a longevity club stocked with IV stations - Fortune - September 23rd, 2024
- How stem cell and gene therapies are revolutionising healthcare - Express Healthcare - September 20th, 2024
- Exploring Regenerative Medicine and Its Impact on Modern Disease Management - Baltimore Post-Examiner - September 18th, 2024
- Stem Cell Therapy Market Dynamics: Size, Share, and Growth - openPR - September 16th, 2024
- Stem Cell Restore Review: Can It Boost Your Stem Cell Activity for Lasting Health? - Vashon-Maury Island Beachcomber - September 14th, 2024
- Stem Cell Therapy Market valued at USD 3.40 Billion by 2030 As Revealed In New Report - WhaTech - September 14th, 2024
- Stem Cell Manufacturing Market Projected to Witness Huge Growth by 2024-2031 As Revealed In New Report - WhaTech - September 14th, 2024
- Tesla BioHealing and Cell Biotechnology Partner to Advance Stem Cell Therapies - Vancity Buzz - September 12th, 2024
- Meso Numismatics Announces Cellgenics Sponsorship of Three Prominent Regenerative Medicine Events in Peru This September - StockTitan - September 10th, 2024
- Meso Numismatics Announces Cellgenics Sponsorship of Three Prominent Regenerative Medicine Events in Peru This September - Newswire - September 10th, 2024
- Breakthrough in blood stem cell development offers hope for leukemia and bone marrow failure - News-Medical.Net - September 8th, 2024
- Stem Cell Therapy Market Is Estimated To Reach $928.6 Million by 2031 | CAGR 16.2% - EIN News - September 8th, 2024
- USC researchers receive funding to develop next generation of intelligent biocomputers - EurekAlert - September 8th, 2024
- Risk Factors and Indications for Stem Cell Transplants in MDS - Targeted Oncology - September 6th, 2024
- Cell Therapy Market Size to Hit USD 28.98 Billion by 2032, - GlobeNewswire - September 6th, 2024
- Blood stem cells grown in the lab for the first time ever - Earth.com - September 6th, 2024
- Top 3 Grants in Regenerative Medicine: August 2024 - RegMedNet - September 6th, 2024
- New approach moves cell therapy closer to treating many disorders - Medical Xpress - September 4th, 2024
- Stem Cell Therapy Mexico: R3 Stem Cell Unveils Innovative and Affordable Non-Invasive Solutions - openPR - September 4th, 2024
- What Sets Immunotherapy Regenerative Medicine Apart in a Crowded Regenerative Market? - Flaunt Magazine - September 2nd, 2024
- Tiny Test Tubes Sort Stem Cells for Improved Therapy - The Scientist - August 31st, 2024
- Dr. Crandall: Stem Cell Treatment Heals the Heart - Newsmax - August 31st, 2024
- From stem cells to technology, the next Wisconsin RISE initiative focuses on improving health - University of Wisconsin-Madison - August 29th, 2024
- aHSCT Stem Cell Therapy for MS | National MS Society - National MS Society - August 29th, 2024
- Are Stem Cells the Secret to Anti-Aging? - The Edge - August 22nd, 2024
- A Comprehensive Review of the Role of Stem Cells in Neuroregeneration: Potential Therapies for Neurological Disorders - Cureus - August 22nd, 2024
- Scientists discover method to activate dormant stem cells in the brain - Medical Xpress - August 20th, 2024
- New way to extend 'shelf life' of blood stem cells can improve gene therapy - Medical Xpress - August 20th, 2024
- Where Are the Cell Therapies for Type 1 Diabetes? - Inside Precision Medicine - August 14th, 2024
- BioRestorative Therapies Reports Second Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire - August 14th, 2024
- Stem Cell Therapy Market to expand to a market value of USD 3.40 Billion by 2030, with a CAGR of 13.4 percentage - openPR - August 14th, 2024
- Stem cell therapy unveiled: Discover the truth and boost donor rates - IOL - August 12th, 2024
- Stem Cell Therapy Market Set to Skyrocket to $48.89 Billion by 2033, Fueled by 13.2% CAGR - BioSpace - August 10th, 2024
- T.J. Watt Reveals He Received Stem Cell Treatment On Knee This Offseason - Steelers Depot - August 10th, 2024
- Anti-aging enthusiasts are getting $16,500 injections to make their knees young again - Business Insider Nederland - August 10th, 2024
- Regenerative Medicine Market Exclusive Insights on Size, Share and Profit - WhaTech - August 8th, 2024
- Fresh Study Reveals the Mesenchymal Stem Cells Market Trends, Strategy and Overview - WhaTech - August 6th, 2024
- Allogeneic Stem Cell Transplantation Market Exclusive Survey Report with Detailed Analysis to 2031 By Top R... - WhaTech - August 6th, 2024
- Salk awarded $3.6 million by the California Institute for Regenerative Medicine to advance research on brain aging - Salk Institute - August 2nd, 2024
- Professor awarded grant to study stem cell therapy for inflammatory bowel disorders - Mercer University - August 2nd, 2024
- Stem cell therapy advances: MSCs show potential in managing COVID-19 and influenza infections - News-Medical.Net - July 31st, 2024
- Scientists aboard international space station perform stem cell research and biomanufacturing in microgravity - BioProcess Insider - July 31st, 2024
- UCLA receives $2 million to develop regenerative medicine therapies for spinal cord injury - UCLA Newsroom - July 31st, 2024
- The Phoenix of stem cells: pluripotent cells in adult tissues and peripheral blood - Frontiers - July 31st, 2024
- Regenerative Medicine Market to Reach USD 194.9 Billion by 2032 - Market.us Media - United States Market News - July 31st, 2024
- Stem Cell Exosome Therapeutic Market Business Insights, Key Trend Analysis - Economica - July 31st, 2024
- One of the 7 people cured of HIV tells his story. Can his cure work for others? - Michigan Public - July 31st, 2024
- Novel stem cell treatment for osteoarthritis reduces pain by 58% - NewsBytes - July 30th, 2024
- Stem Cell Manufacturing Market Size To Reach $21.8 Billion By 2028 As Revealed In New Report - WhaTech - July 30th, 2024
- PRP, stem cell therapyhelp in curing infertility - The Times of India - July 30th, 2024
- Australian researchers develop a donor stem cell therapy for the successful treatment of osteoarthritis - News Hub - July 28th, 2024
- Seventh patient cured of HIV: why scientists are excited - Nature.com - July 28th, 2024
- Enggartiasto Lauds Stem Cell Therapy at RSCM - Jakartaglobe.id - July 28th, 2024
- Investigating the effect of alemtuzumab in allogeneic hematopoietic cell transplantation - Medical Xpress - July 28th, 2024
- Does This 'Stem Cell' Therapy Contain Any Actual Stem Cells? - Medscape - July 22nd, 2024
- Stem Cells and Malignant Mesothelioma - Mesothelioma.net Blog - July 18th, 2024
- Selma Blair on Getting Back on Track With MS Treatment: People Dont Get How Expensive It Is to Be Disabled - Hollywood Reporter - July 18th, 2024
- Common therapies contain different cell types, study finds - News-Medical.Net - July 18th, 2024
- Stem Cell Therapy with Saffron Extract Promotes Uterine Healing - Natural Science News - July 18th, 2024
- Half-matched stem cell transplant on 11-yr-old boy - The Times of India - July 12th, 2024
- Efficacy and Safety of Stem Cell Therapy for Orthopedic Conditions, Including Osteoarthritis and Bone Defects - Cureus - July 8th, 2024
- Stem Cell Therapy Market Poised to Reach USD 52.1 Billion by 2034 at a 12.1% of CAGR - PharmiWeb.com - July 8th, 2024
- "Living Fillings" Could be the Future Thanks to Stem Cells - NewBeauty Magazine - July 8th, 2024
- R3 Stem Cell Wins 2024 Global Regenerative Medicine Company of the Year for Third Time - EIN News - July 8th, 2024
- NUS Medicine team aims to start clinical trial of targeted therapy for deadly brain cancer in 2025 - The Straits Times - July 8th, 2024
- Sorting therapeutic stem cells by function improves healing after heart attack, lab study shows - Medical Xpress - July 4th, 2024
- July: cruk-grant | News and features - University of Bristol - July 4th, 2024
- Stem cell therapy shows promise for hirschsprung disease - Open Access Government - June 30th, 2024
- Stem Cells & Other Injectable Treatments: Solution or Scam? Episode 3 of 'The Bone Whisperers' Podcast - NYU Langone Health - June 28th, 2024
- Modulation of adipose-derived stem cell behavior by prostate pathology-associated plasma: insights from in vitro ... - Nature.com - June 28th, 2024
- Advancing regenerative medicine therapies UCI News - UCI News - June 26th, 2024
- Stem cell therapy could be breakthrough against type 1 diabetes - Medical Xpress - June 26th, 2024
- Paving the Way Toward Transplantation: NIH Awards Support Ophthalmology Retinal Research - University of Colorado Anschutz Medical Campus - June 26th, 2024
- Stem Cell Therapy Could Be Breakthrough Against Type 1 Diabetes - The Caledonian-Record - June 26th, 2024
Recent Comments